drugset / Trial / NCT05166070
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Phase 0
Recruiting
24 enrolled
The First Affiliated Hospital with Nanjing Medical University
Shanghai IASO Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-01-01
- Completion
- 2037-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RD133 | Cell therapy | 1 cells/kg | Intravenous |
| Subject | RD133 | Cell therapy | 3 cells/kg | Intravenous |
| Subject | RD133 | Cell therapy | 6 cells/kg | Intravenous |